[Myelodysplastic syndrome with erythroblastopenia].
Myelodysplastic syndrome with erythroid hypoplasia or erythroblastopenia has not yet been clearly defined, and in most patients it is mistaken for acquired pure red cell aplasia. Including one additional patient reported in this article, a literature review revealed only 50 cases over the last 20 years. These patients were predominantly elderly males, all required regular packed red cell transfusions, and they had a poor prognosis, mainly because of acute transformation. The mechanisms of erythroid aplasia remain unclear. However, recent data suggest the association of an intrinsic stem cell defect with immunological implication.
Martinaud
C
C
Fédération des laboratoires, HIA Sainte-Anne, 2 boulevard Sainte-Anne, Toulon cedex 9, France. christophe.martinaud@inserm.fr
Pons
S
S
Ménard
G
G
Gisserot
O
O
de Jaureguiberry
J-P
JP
Brisou
P
P
D017677:Age Distribution; D001803:Blood Transfusion; D003937:Diagnosis, Differential; D004900:Erythroblasts / Q000473:pathology; D004921:Erythropoietin / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005602:France / Q000453:epidemiology; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D011379:Prognosis; D012010:Red-Cell Aplasia, Pure / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D012307:Risk Factors; D017678:Sex Distribution
D004921:Erythropoietin